Perspectives

Pharmacist intervention may help identify potential opioid abuse early

Concurrent drug utilization review catches opioid abuse upstream

July 21, 2016

Concurrent drug utilization review (DUR) may cast wider net for catching potential opioid abuse upstream

A pharmacist intervention (DUR) may impact potential opioid misuse and abuse. This study identified at-risk members at the time they submit their opioid prescription. A soft edit (point of service) intervention delayed or altered claims for 42% of the members in the study.

Impact of a Concurrent Drug Utilization Review Edit Designed to Curb Opioid Misuse (Spring 2016)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime provides total drug management solutions for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and offers clinical services for people with complex medical conditions. Prime serves more than 33 million people. It is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans.

Related news

Perspectives

August 15, 2022

September 2022 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…

Read More

Perspectives

August 4, 2022

Specialty Pipeline Update: July 2022

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Read More

Perspectives

August 4, 2022

Traditional Drug Pipeline Update: July 2022

This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…

Read More
View all news